[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2662
51. Burry LD, Tung DD, Hallett D, Bailie T, Carvalhana V, Lee D, Ramganesh S, Richardson R, Mehta S, Lapinsky SE: Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. Ann Pharmacother; 2009 Sep;43(9):1419-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, RCA has been associated with significant metabolic complications including hypocalcemia, hypernatremia, metabolic alkalosis, and citrate toxicity.
  • OBJECTIVE: To describe our experience with a newly implemented RCA protocol with acid citrate dextrose formula A (ACD-A) and intravenous calcium gluconate, for use with PrismaFlex CRRT in critically ill patients with acute kidney injury.
  • Six patients, 3 with acute leukemia, required transfusion of 2 or more units of packed red blood cells in 24 hours.
  • [MeSH-major] Acute Kidney Injury / therapy. Anticoagulants / administration & dosage. Citric Acid / administration & dosage. Glucose / analogs & derivatives. Renal Replacement Therapy / methods

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. CALCIUM GLUCONATE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. CITRIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19690224.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 13838-07-8 / acid citrate dextrose; 2968PHW8QP / Citric Acid; IY9XDZ35W2 / Glucose; SQE6VB453K / Calcium Gluconate
  •  go-up   go-down


52. Wu LP, Chen FX, Lu HM, Wu ZL, Wu ZL: [Biological characteristics of bone marrow-derived mesenchymal stem cells in children with acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun;17(3):734-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biological characteristics of bone marrow-derived mesenchymal stem cells in children with acute leukemia].
  • This study was aimed to investigate the conditions of culturing in vitro mesenchymal stem cells (MSCs) derived from bone marrow of children with acute leukemia and the biological characteristics of MSCs from leukemia children.
  • The bone marrow MSCs of acute leukemia children were isolated by density gradient centrifugation combined with adherent segregating method and cultured in DMEM/F12.
  • The morphology of Wright stained MSCs was observed under inverted microscope.
  • Cell surface markers were analyzed with flow cytometry.
  • The results indicated that BM-MSCs of acute leukemia children could be successfully cultured in vitro in appropriate conditions.
  • The MSCs from leukemia children could be induced into adipocytes and osteocytes in appropriate conditions.
  • It is concluded that (1) MSCs derived from children with acute leukemia can be successfully cultured and passaged in vitro;.
  • (2) MSCs from leukemia children not received chemotherapy are more successfully cultured in vitro than those received chemotherapy;.
  • (3) the common biological characteristics of MSCs from children with acute leukemia are same as the MSCs from healthy person.


53. Abdulsalam AH: Chemotherapeutic trial for acute leukemia in Iraq. Turk J Haematol; 2009 Dec 5;26(4):216
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapeutic trial for acute leukemia in Iraq.
  • [Transliterated title] Irak'ta akut lösemi için kemoterapötik deneme.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265640.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


5
Advertisement
4. Iguchi T, Yamada Y, Awaya N, Ikeda Y, Okamoto S, Kizaki M: Multilineage involvement of light microscopic myeloperoxidase-negative acute leukemia. Int J Hematol; 2005 Nov;82(4):315-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multilineage involvement of light microscopic myeloperoxidase-negative acute leukemia.
  • The classification of acute leukemia has traditionally been based on a combination of morphology and cytochemical staining data, including myeloperoxidase (MPO) reaction; however, a recent World Health Organization (WHO) classification entails use of cytogenetic and molecular findings in addition to the classic morphological and immunophenotypic analyses.
  • These cases may be classified as acute leukemia of ambiguous lineage in the recent WHO classification.
  • We report the case of a 49-year-old man with acute leukemia with multilineage phenotypes.
  • Morphological findings led to a diagnosis of acute myeloid leukemia M2 by the French-American-British classification, but at light microscopy the results of MPO staining were negative for blast cells.
  • In contrast, results of reverse transcription polymerase chain reaction and fluorescence-activated cell sorter analyses were positive for expression of MPO messenger RNA and protein.
  • The blast cells expressed CD4, CD19, CD22, CD33, CD38, CD79a, and HLA-DR and showed rearrangement of the immunoglobulin heavy chain and TCR-3 genes.
  • Results of immunoelectron microscopic analysis of the blast cells were positive for MPO, CD19, CD33, CD34, CD38 and glycophorin A but not for platelet peroxidase.
  • According to these results, the blast cells had at least 4 lineage phenotypes.
  • We concluded that the multiparameter analyses conducted in this case, including immunological and ultrastructural assays, were important in arriving at the appropriate diagnosis of acute leukemia of ambiguous lineage in the new WHO classification.
  • [MeSH-major] Bone Marrow Cells / pathology. Leukemia / pathology. Peroxidase / genetics
  • [MeSH-minor] Acute Disease. Antigens, CD / analysis. Antigens, CD / genetics. Gene Rearrangement. HLA-DR Antigens / analysis. HLA-DR Antigens / genetics. Humans. Immunophenotyping. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1998 Dec;12(12):2038 [9844938.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Haematologica. 1999 Aug;84(8):699-706 [10457405.001]
  • [Cites] Blood. 1990 Aug 15;76(4):808-13 [2166608.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Leuk Lymphoma. 1999 Jul;34(3-4):395-9 [10439377.001]
  • [Cites] Br J Haematol. 1988 Jun;69(2):205-11 [3390393.001]
  • [Cites] J Exp Med. 1989 Mar 1;169(3):1101-20 [2538542.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jan;81(1):253-7 [6607471.001]
  • [Cites] Leukemia. 1996 Aug;10(8):1283-7 [8709632.001]
  • (PMID = 16298822.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / HLA-DR Antigens; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


55. Malfuson JV, Margery J, Bonnichon A, Fagot T, Souleau B, Samson T, de Revel T: [Acute respiratory distress revealing acute myeloblastic leukaemia: case report]. Rev Pneumol Clin; 2010 Sep;66(4):276-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute respiratory distress revealing acute myeloblastic leukaemia: case report].
  • We report on the case of a patient diagnosed with acute leukaemic transformation of chronic myelomonocytic leukaemia.
  • We discuss the etiologies of respiratory distress in acute myeloblastic leukaemia and the corticosteroid sensitivity of this myeloid disease.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / diagnosis. Respiratory Distress Syndrome, Adult / etiology
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Glucocorticoids / therapeutic use. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 20933171.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


56. Baruchel A, Leblanc T, Auclerc MF, Schaison G, Leverger G: [Towards cure for all children with acute lymphoblastic leukemia?]. Bull Acad Natl Med; 2009 Oct;193(7):1509-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Towards cure for all children with acute lymphoblastic leukemia?].
  • [Transliterated title] Vers la guérison de tous les enfants atteints de leucémie aiguë lymphoblastique?
  • Childhood acute lymphoblastic leukemia is a model in oncology.
  • The current aims are to de-escalate treatment for better-defined low-risk groups, and to develop the use of new drugs and targeted therapies for high-risk groups, based on genome-wide analysis of the patient and the leukemic cell.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Drug Resistance, Neoplasm. Humans. Immunophenotyping. Infant. Multicenter Studies as Topic / statistics & numerical data. Prognosis. Randomized Controlled Trials as Topic / statistics & numerical data. Remission Induction. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20669632.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 23
  •  go-up   go-down


57. Thomas X: [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. Bull Cancer; 2007 Oct;94(10):871-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
  • [Transliterated title] Leucémie aiguë lymphoblastique à chromosome Philadelphie: traitement par les inhibiteurs de kinases.
  • Distinct clinicopathologic acute lymphoblastic leukemia (ALL) entities have been identified, resulting in the adoption of risk-oriented treatment approaches.
  • The emergence of resistance to the Bcr-Abl inhibitor imatinib mesylate in patients with Philadelphia chromosome-positive (Ph+) ALL has prompted the development of second-generation compounds active against mutant forms, including dasatinib and nilotinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Protein Kinase Inhibitors / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964981.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrimidines; 0 / Pyrroles; 0 / Thiazoles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 639089-54-6 / VX680; 8A1O1M485B / Imatinib Mesylate; 9ZOQ3TZI87 / sorafenib; EC 2.5.- / Alkyl and Aryl Transferases; EC 2.5.1.- / p21(ras) farnesyl-protein transferase; EC 2.7.10.2 / Fusion Proteins, bcr-abl; RBZ1571X5H / Dasatinib
  • [Number-of-references] 115
  •  go-up   go-down


58. Ohyashiki JH, Umezu T, Kobayashi C, Hamamura RS, Tanaka M, Kuroda M, Ohyashiki K: Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes; 2010;3:347
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a.
  • Our aim was to determine the biological relevance of miR-92a, which has been implicated as an oncomiR in both plasma and leukemia cells in patients with acute leukemia and to evaluate whether it could be a novel biomarker for monitoring these patients.
  • RESULTS: We quantified the expression level of miR-92a in both cells and plasma by reverse transcription polymerase chain reaction in 91 patients with acute leukemia.
  • We compared miR-92a expression in plasma with its expression in leukemia cells.
  • The level of miR-92a expression in fresh leukemia cells was highly variable compared with PBMNC, but significantly lower compared with CD34-positive cells obtained from healthy volunteers.
  • We also noticed that miR-92a was preferentially expressed in acute lymphoblastic leukemia (ALL) cells in comparison with acute myeloid leukemia (AML) cells.
  • Notably, the cell to plasma ratio of miR-92a expression was significantly higher in both AML and ALL cells compared with PBMNC from healthy volunteers.
  • CONCLUSIONS: The miR-92a expression in leukemia cells could be a prognostic factor in ALL patients.
  • The inverse correlation of miR-92a expression between cells and plasma and the cell to plasma ratio may be important to understanding the clinical and biological relevance of miR-92a in acute leukemia.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40 [18832181.001]
  • [Cites] Nat Immunol. 2008 Aug;9(8):839-45 [18645592.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5473-7 [19706812.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4169-78 [19749093.001]
  • [Cites] PLoS One. 2009;4(11):e7826 [19915715.001]
  • [Cites] Sci Signal. 2009 Dec 8;2(100):ra81 [19996457.001]
  • [Cites] J Biol Chem. 2010 Jun 4;285(23):17442-52 [20353945.001]
  • [Cites] Br J Cancer. 2009 Sep 1;101(5):743-8 [19672257.001]
  • [Cites] Br J Haematol. 2008 May;141(5):672-5 [18318758.001]
  • [Cites] Cancer Sci. 2008 Jun;99(6):1147-54 [18429962.001]
  • [Cites] Am J Pathol. 2008 Sep;173(3):856-64 [18688024.001]
  • [Cites] Blood. 2009 Jan 8;113(2):396-402 [18941111.001]
  • [Cites] Blood. 2009 Jun 18;113(25):6411-8 [19211935.001]
  • [Cites] Cancer Sci. 2009 May;100(5):970-7 [19298223.001]
  • [Cites] PLoS One. 2009;4(5):e5532 [19440243.001]
  • [Cites] Br J Cancer. 2009 Aug 18;101(4):551-6 [19638982.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Nat Rev Genet. 2004 Jul;5(7):522-31 [15211354.001]
  • [Cites] J Interferon Cytokine Res. 2005 Jan;25(1):1-10 [15684617.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Oncogene. 2007 Sep 6;26(41):6099-105 [17384677.001]
  • [Cites] Nucleic Acids Res. 2007 Jul;35(Web Server issue):W339-44 [17553836.001]
  • [Cites] Blood. 2008 May 15;111(10):5078-85 [18337557.001]
  • [Cites] Leuk Res. 2009 Sep;33(9):1217-23 [19195700.001]
  • (PMID = 21182798.001).
  • [ISSN] 1756-0500
  • [Journal-full-title] BMC research notes
  • [ISO-abbreviation] BMC Res Notes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3022817
  •  go-up   go-down


59. Kelly K, Storey L, O' Sullivan M, Butler K, McDermott M, Corbally M, McMahon C, Smith OP, O' Marcaigh A: Esophageal strictures during treatment for acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2010 Mar;32(2):124-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal strictures during treatment for acute lymphoblastic leukemia.
  • We describe 4 cases of esophageal stricture during chemotherapy for acute lymphoblastic leukemia.
  • The etiology of esophageal strictures during treatment for acute leukemia is likely to be multifactorial but systemic candidiasis may play a significant role.
  • [MeSH-major] Esophageal Stenosis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168244.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antineoplastic Agents; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


60. Koppel A, Schiller G: Myelodysplastic syndrome: an update on diagnosis and therapy. Curr Oncol Rep; 2008 Sep;10(5):372-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelodysplastic syndrome: an update on diagnosis and therapy.
  • Despite the variable risk of transformation to acute leukemia, the majority of deaths are due to bone marrow failure.
  • No truly effective treatment exists for MDS, and therapy usually focuses on reducing or preventing complications of the disease.
  • [MeSH-major] Leukemia / diagnosis. Leukemia / therapy. Myelodysplastic Syndromes / diagnosis. Myelodysplastic Syndromes / therapy


61. Heddle NM, Cook RJ, Sigouin C, Slichter SJ, Murphy M, Rebulla P, BEST Collaborative (Biomedical Excellence for Safer Transfusion): A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion; 2006 Jun;46(6):903-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia.
  • RESULTS: A total of 897 patients with acute leukemia received 10,506 PLT transfusions.
  • [MeSH-major] Hemorrhage / prevention & control. Leukemia / complications. Leukemia / therapy. Platelet Transfusion
  • [MeSH-minor] Acute Disease. Canada. Data Collection. Great Britain. Humans. Incidence. Italy. Platelet Count. Randomized Controlled Trials as Topic. Retrospective Studies. United States


62. Karp JE, Giles FJ, Gojo I, Morris L, Greer J, Johnson B, Thein M, Sznol M, Low J: A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk Res; 2008 Jan;32(1):71-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
  • We designed a Phase I trial of Triapine followed by the adenosine analog fludarabine in adults with refractory acute leukemias and aggressive myeloproliferative disorders (MPD).
  • Complete and partial responses (CR, PR) occurred in Schedule A (5/24, 21%), with CR occurring at the 2 highest fludarabine doses (2/12, 17%).
  • In contrast, no CR or PR occurred in Schedule B.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Apr 27;332(17):1132-6 [7700286.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(3):181-8 [7781136.001]
  • [Cites] J Med Chem. 1996 Jun 21;39(13):2586-93 [8691457.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2480-7 [8839839.001]
  • [Cites] Blood. 1997 Jul 1;90(1):270-8 [9207462.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2780-5 [9256119.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2321-31 [9667246.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):647-55 [9722289.001]
  • [Cites] Leuk Res. 2006 Jul;30(7):813-22 [16478631.001]
  • [Cites] Leuk Res. 2007 Sep;31(9):1165-73 [17324462.001]
  • [Cites] Biochem Pharmacol. 2000 Apr 15;59(8):983-91 [10692563.001]
  • [Cites] Leukemia. 2000 Mar;14(3):379-88 [10720130.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3671-4 [11090046.001]
  • [Cites] Prog Biophys Mol Biol. 2001 Nov;77(3):177-268 [11796141.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1369-77 [12168813.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4272-90 [12393615.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1920-8 [12673719.001]
  • [Cites] Leuk Res. 2003 Dec;27(12):1077-83 [12921943.001]
  • [Cites] Jpn J Cancer Res. 1985 Aug;76(8):729-35 [3930450.001]
  • [Cites] J Clin Oncol. 1986 Jan;4(1):74-9 [2416889.001]
  • [Cites] Cancer Treat Rep. 1986 Oct;70(10):1225-8 [2428492.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):329-34 [3335008.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):222-6 [2554751.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):175-88 [1702143.001]
  • [Cites] Biochem Cell Biol. 1990 Dec;68(12):1364-71 [2085432.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2937-44 [1954383.001]
  • [Cites] Ann Hematol. 1992 Jul;65(1):26-32 [1643157.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):116-24 [8418222.001]
  • [Cites] Blood. 1993 Jul 15;82(2):398-407 [8329700.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26200-5 [8253740.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):671-8 [7512125.001]
  • [Cites] Biochem Pharmacol. 1994 Jul 19;48(2):335-44 [8053929.001]
  • [Cites] Anal Biochem. 1994 Oct;222(1):116-22 [7856836.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Cancer Res. 1971 Mar;31(3):235-8 [5102115.001]
  • [Cites] Blood. 1975 Jul;46(1):11-6 [1055610.001]
  • [Cites] Cancer Res. 1980 Sep;40(9):3286-92 [7427943.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2688-93 [6189585.001]
  • (PMID = 17640728.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070095-14; United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / U01 CA070095; United States / NCRR NIH HHS / RR / M01 RR000052; United States / NCI NIH HHS / CA / CA070095-14
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Pyridines; 0 / Thiosemicarbazones; 143621-35-6 / 3-aminopyridine-2-carboxaldehyde thiosemicarbazone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ NIHMS35421; NLM/ PMC2726775
  •  go-up   go-down


63. Watanabe-Okochi N, Oki T, Komeno Y, Kato N, Yuji K, Ono R, Harada Y, Harada H, Hayashi Y, Nakajima H, Nosaka T, Kitaura J, Kitamura T: Possible involvement of RasGRP4 in leukemogenesis. Int J Hematol; 2009 May;89(4):470-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously established a mouse bone marrow-derived HF6, an IL-3-dependent cell line, that was immortalized by a class II mutation MLL/SEPT6 and can be fully transformed by class I mutations such as FLT3 mutants.
  • To understand the molecular mechanism of leukemogenesis, particularly progression of myelodysplastic syndrome (MDS) to acute leukemia, we made cDNA libraries from the samples of patients and screened them by expression-cloning to detect class I mutations that render HF6 cells factor-independent.
  • C57BL/6J mice transplanted with RasGRP4-transduced primary bone marrow cells died of T cell leukemia, myeloid leukemia, or myeloid leukemia with T cell leukemia.
  • The double transduction led to early onset of T cell leukemia but not of AML in the transplanted mice when compared to transduction of RasGRP4 alone.
  • Thus, we have identified RasGRP4 as a gene potentially involved in leukemogenesis and suggest that RasGRP4 cooperates with AML1 mutations in T cell leukemogenesis as a class I mutation.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Leukemia / metabolism. Leukemia / pathology. ras Guanine Nucleotide Exchange Factors / metabolism
  • [MeSH-minor] Animals. Cell Line. Cell Proliferation. Core Binding Factor Alpha 2 Subunit / genetics. Core Binding Factor Alpha 2 Subunit / metabolism. Gene Expression Regulation, Neoplastic. Humans. Mice. Mutation / genetics. Neoplasm Transplantation. Polymorphism, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Feb 15;101(4):1277-83 [12393381.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30508-14 [11880369.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):919-29 [15761502.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2776-84 [17957027.001]
  • [Cites] Leukemia. 2006 Apr;20(4):635-44 [16467864.001]
  • [Cites] Leukemia. 2006 Jun;20(6):965-70 [16598313.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1806-9 [16291592.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] Hematol J. 2002;3(6):283-9 [12522450.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):950-6 [16404744.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):775-7 [12780793.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3768-76 [16105978.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8283-8 [12060771.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2249-56 [17968322.001]
  • [Cites] Br J Haematol. 2005 Nov;131(4):495-507 [16281942.001]
  • [Cites] Int J Hematol. 1998 Jun;67(4):351-9 [9695408.001]
  • [Cites] Leukemia. 1994 Feb;8(2):258-63 [7508533.001]
  • [Cites] Br J Haematol. 2003 Jan;120(1):89-92 [12492581.001]
  • [Cites] Blood. 2000 Jan 15;95(2):726-7 [10660321.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9146-50 [7568090.001]
  • [Cites] Exp Hematol. 2003 Nov;31(11):1007-14 [14585362.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4297-308 [18192504.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3589-95 [11369655.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 [15650049.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2185-9 [12399960.001]
  • [Cites] Leukemia. 2005 Oct;19(10 ):1794-805 [16094415.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):274-81 [12042700.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1708-15 [16675706.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2232-40 [16281072.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2316-24 [14615365.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2492-9 [14562119.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1085-8 [14504097.001]
  • [Cites] Oncogene. 2001 Dec 13;20(57):8236-48 [11781838.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):110-8 [14695990.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1153-60 [15889156.001]
  • [Cites] Haematologica. 2004 Aug;89(8):920-5 [15339674.001]
  • [Cites] J Biol Chem. 2007 Jun 22;282(25):17997-8008 [17438331.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25756-74 [11956218.001]
  • [Cites] J Clin Invest. 2005 Aug;115(8):2159-68 [16025155.001]
  • (PMID = 19350351.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RASGRP4 protein, human; 0 / Rasgrp4 protein, mouse; 0 / ras Guanine Nucleotide Exchange Factors
  •  go-up   go-down


64. Uesato N, Fukui K, Maruhashi J, Tojo A, Tajima N: JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model. Exp Hematol; 2006 Oct;34(10):1385-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model.
  • OBJECTIVE: Accumulating findings suggest that in acute myeloid leukemia (AML) patients, proinflammatory cytokines and growth factors play important roles in the proliferation and survival of AML cells in an autocrine and paracrine manner, leading to deterioration of AML.
  • In the present study, we investigated the potency of JTE-607 as an antileukemic agent by exploiting a SCID mouse acute leukemia model.
  • Delayed administration of JTE-607 also prolonged the survival of mice bearing established leukemia with an effect comparable to the maximum tolerable dose of cytarabine.
  • [MeSH-major] Cytokines / antagonists & inhibitors. Leukemia, Myeloid, Acute / drug therapy. Phenylalanine / analogs & derivatives. Piperazines / pharmacology
  • [MeSH-minor] Animals. Antigens, CD45 / blood. Autocrine Communication / drug effects. Cell Proliferation / drug effects. Disease Models, Animal. Drug Evaluation, Preclinical. Female. Humans. Interleukin-8 / blood. Mice. Mice, SCID. Neoplasm Transplantation. Neoplasms, Experimental / drug therapy. Paracrine Communication / drug effects. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982331.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-8; 0 / JTE 607; 0 / Piperazines; 47E5O17Y3R / Phenylalanine; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


65. Veneri D, Franchini M, Krampera M, de Matteis G, Solero P, Pizzolo G: Analysis of HFE and TFR2 gene mutations in patients with acute leukemia. Leuk Res; 2005 Jun;29(6):661-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of HFE and TFR2 gene mutations in patients with acute leukemia.
  • We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C).
  • Mean serum ferritin levels at diagnosis were increased (822.5+/-811.4 microg/L).
  • [MeSH-major] Histocompatibility Antigens Class I / genetics. Membrane Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Transferrin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863206.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HFE protein, human; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins; 0 / Receptors, Transferrin; 0 / TFR2 protein, human
  •  go-up   go-down


66. Huh JY, Chung S, Oh D, Kang MS, Eom HS, Cho EH, Han MH, Kong SY: Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: a report of 2 cases with a review of the literature. Korean J Lab Med; 2010 Apr;30(2):117-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: a report of 2 cases with a review of the literature.
  • The translocation t(10;11)(p13;q14q21) has been found to be recurrent in acute lymphoblastic and myeloid leukemias, and results in the fusion of the clathrin assembly lymphoid myeloid leukemia (CALM) gene with the AF10 gene; these genes are present on chromosomes 11 and 10, respectively.
  • Because the CALM-AF10 rearrangement is a rare chromosomal abnormality, it is not included in routine molecular tests for acute leukemia.
  • The first patient (case 1) was diagnosed with T-cell ALL, and the second patient (case 2) was diagnosed with AML.
  • Both patient samples showed expression of the homeobox A gene cluster and the histone methyltransferase hDOT1L, which suggests that they mediate leukemic transformation in CALM-AF10-positive and mixed-lineage leukemia-AF10-positive leukemias.
  • The first patient (case 1) relapsed after double-unit cord blood transplantation; there was no evidence of relapse in the second patient (case 2) after allogenic peripheral blood stem cell transplantation.
  • Since CALM-AF10- positive leukemias have been shown to have poor prognosis with conventional therapy, molecular tests for CALM-AF10 rearrangement would be necessary to detect minimal residual disease during follow-up.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Monomeric Clathrin Assembly Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 11. Cord Blood Stem Cell Transplantation. Female. Histone-Lysine N-Methyltransferase / genetics. Histone-Lysine N-Methyltransferase / metabolism. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Humans. Male. Recurrence. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20445327.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / MLLT10 protein, human; 0 / Monomeric Clathrin Assembly Proteins; 0 / Oncogene Proteins, Fusion; 0 / PICALM protein, human; 0 / Transcription Factors; EC 2.1.1.- / histone methyltransferase; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 14
  •  go-up   go-down


67. Schalk E, Mohren M, Jentsch-Ullrich K, Dombrowski F, Franke A, Koenigsmann M: Zygomycoses in patients with acute leukaemia. Ann Hematol; 2006 May;85(5):327-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zygomycoses in patients with acute leukaemia.
  • The high mortality rate is due to a high failure rate of both intravital diagnosis and treatment.
  • Exact diagnosis requires microscopic examination and proof by culture.
  • We report four recent cases of zygomycosis among 89 patients with intensively treated acute leukaemia at our institution.
  • Three cases were breakthrough infections since the patients were under voriconazole treatment prior to diagnosis of zygomycosis.
  • Only one patient had premortal diagnosis (paranasal sinus infection) and showed clinical response with amphotericin B and surgical debridement.
  • A review of the literature of these emerging fungal infections is given and is focused on patients with acute leukaemia.
  • [MeSH-major] Amphotericin B / administration & dosage. Antifungal Agents / administration & dosage. Immunocompromised Host. Leukemia. Zygomycosis / diagnosis. Zygomycosis / therapy

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523312.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 7XU7A7DROE / Amphotericin B; JFU09I87TR / Voriconazole
  • [Number-of-references] 39
  •  go-up   go-down


68. Robinson BW, Felix CA: Panhandle PCR approaches to cloning MLL genomic breakpoint junctions and fusion transcript sequences. Methods Mol Biol; 2009;538:85-114
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Translocations and other rearrangements of the MLL gene at chromosome band 11q23 are biologically and clinically important molecular abnormalities in infant acute leukemias, leukemias associated with chemotherapeutic topoisomerase II poisons and, less often, acute leukemias in adults or myelodysplastic syndrome.
  • Depending on the disease and the regimen, MLL-rearranged leukemias may be associated with inferior prognosis, and MLL rearrangements with some of the more than 60 known MLL-partner genes confer especially adverse effects as response to treatment (Blood 108:441-451, 2006).
  • MLL rearrangements are usually evident as overt balanced chromosomal translocations by conventional cytogenetic analysis but up to one-third are cryptic rearrangements and occur in leukemias with del(11)(q23), a normal karyotype, or trisomy 11, the latter two of which sometimes are associated with partial tandem duplications of MLL itself (Proc Natl Acad Sci USA 97:2814-2819, 2000; Proc Natl Acad Sci USA 94:3899-3902, 1997).
  • Rapid and accurate methods to identify and characterize genomic breakpoint junctions and fusion transcripts resulting from the many types of MLL rearrangements are essential for risk group stratification, treatment protocol assignments, new partner gene discovery, understanding leukemia etiology and pathogenesis, and elucidating the impact of less common MLL-partner genes on biology and prognosis.
  • Due to the vast heterogeneity in partner genes, typical gene-specific PCR based methods are not practical, especially when cytogenetics are normal or do not suggest involvement of a known partner gene of MLL.
  • [MeSH-major] Chromosome Breakage. Cloning, Molecular / methods. Leukemia / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277575.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA77683; United States / NCI NIH HHS / CA / CA80175; United States / NCI NIH HHS / CA / CA85469
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


69. Zhou L, Guo X, Jing BA, Zhao L: CD44 is involved in CXCL-12 induced acute myeloid leukemia HL-60 cell polarity. Biocell; 2010 Aug;34(2):91-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44 is involved in CXCL-12 induced acute myeloid leukemia HL-60 cell polarity.
  • CXCL-12 and its receptor CXCR4 participate in breast cancer and melanoma cell metastasis to bone and lymphoid nodes.
  • But the role of CD44 in CXCL-12 induced leukemia cell migration still remains unclear.
  • The present study showed that CXCL-12 stimulation induced the rapid internalization of CXCR4 and facilitated the formation of lamellipodia and uropod in acute leukemia cell line HL-60.
  • CXCL-12 also induced CD44 translocation into the uropod, while CD44 remained evenly distributed on the untreated cell membranes.
  • Results suggest that CD44 participates in CXCL-12 induced cell polarization and subsequent cell migration.
  • [MeSH-major] Antigens, CD44 / immunology. Cell Polarity. Chemokine CXCL12 / immunology. Leukemia, Myeloid, Acute / immunology
  • [MeSH-minor] Animals. Cell Movement / physiology. Cell Surface Extensions / metabolism. HL-60 Cells. Humans. Receptors, CXCR4

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20925198.001).
  • [ISSN] 0327-9545
  • [Journal-full-title] Biocell : official journal of the Sociedades Latinoamericanas de Microscopía Electronica ... et. al
  • [ISO-abbreviation] Biocell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Receptors, CXCR4
  •  go-up   go-down


70. Zee YK, Soo RA: Non-small cell lung cancer presenting with neoplastic fever at diagnosis and relapse. Int J Infect Dis; 2010 Jun;14(6):e518-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small cell lung cancer presenting with neoplastic fever at diagnosis and relapse.
  • Fever occurs frequently in cancer patients, and neoplastic fever is a well-described paraneoplastic phenomenon in patients with lymphoma, acute leukemias, and renal cell carcinoma.
  • It is also more commonly encountered in metastatic disease.
  • Treatment options include disease-specific therapy, non-steroidal anti-inflammatory drugs (NSAIDs), and steroids.
  • In this report, we describe an unusual case of non-metastatic non-small cell lung cancer (NSCLC) presenting with neoplastic fever at both diagnosis and relapse, responding on each occasion to disease-specific treatment, and provide a review of the management of neoplastic fever.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Fever / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19699672.001).
  • [ISSN] 1878-3511
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


71. Ravandi F, Kebriaei P: Cytokines in the treatment of acute leukemias. Cancer Treat Res; 2005;126:313-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokines in the treatment of acute leukemias.
  • [MeSH-major] Cytokines / therapeutic use. Leukemia / therapy
  • [MeSH-minor] Acute Disease. Humans

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16209072.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 88
  •  go-up   go-down


72. Glatting G, Müller M, Koop B, Hohl K, Friesen C, Neumaier B, Berrie E, Bird P, Hale G, Blumstein NM, Waldmann H, Bunjes D, Reske SN: Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med; 2006 Aug;47(8):1335-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia.
  • The outcome of hematopoietic cell transplantation for hematologic malignancies may be improved by delivering targeted radiation to hematopoietic organs while relatively sparing nontarget organs.
  • [MeSH-major] Antibodies, Monoclonal / chemistry. Antigens, CD45 / chemistry. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Aged. Bone Marrow Transplantation. Female. Humans. Male. Middle Aged. Stem Cell Transplantation. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883014.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G7904009
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / YAML568 monoclonal antibody; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


73. Vollmer RT: Blast counts in bone marrow aspirate smears: analysis using the poisson probability function, bayes theorem, and information theory. Am J Clin Pathol; 2009 Feb;131(2):183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blast counts in bone marrow aspirate smears: analysis using the poisson probability function, bayes theorem, and information theory.
  • Herein, I introduce and demonstrate these mathematical functions for the analysis of counts of blasts in marrow aspirates and explore the uncertainty that naturally arises when counts of blasts are near cut points used to separate the categories of refractory anemia without excess blasts, refractory anemia with excess blasts, and acute leukemia.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / diagnosis. Bayes Theorem. Bone Marrow Cells / pathology. Cell Count / statistics & numerical data. Leukemia / diagnosis. Poisson Distribution. Probability

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Pathol. 2009 Jul;132(1):147-8; author reply 148 [19864247.001]
  • (PMID = 19141378.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


74. Shahsavar F, Tajik N, Entezami KZ, Fallah Radjabzadeh M, Asadifar B, Alimoghaddam K, Ostadali Dahaghi M, Jalali A, Ghashghaie A, Ghavamzadeh A: KIR2DS3 is associated with protection against acute myeloid leukemia. Iran J Immunol; 2010 Mar;7(1):8-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIR2DS3 is associated with protection against acute myeloid leukemia.
  • BACKGROUND: Interaction between killer cell immunoglobulin-like receptors (KIR) and human leukocyte antigen (HLA) class I molecules is important for regulation of natural killer (NK) cell function.
  • OBJECTIVE: The aim of this study was to investigate the impact of compound KIR-HLA genotype on susceptibility to acute leukemia.
  • METHODS: Cohorts of Iranian patients with acute myeloid leukemia (AML; n=40) and acute lymphoid leukemia (ALL; n=38) were genotyped for seventeen KIR genes and their three major HLA class I ligand groups (C1, C2, Bw4) by a combined polymerase chain reaction-sequence-specific primers (PCR-SSP) assay.
  • Other analyses including KIR genotypes, distribution and balance of inhibitory and activating KIR+HLA combinations, and co-inheritance of activating KIR genes with inhibitory KIR+HLA pairs were not significantly different between leukemia patients and the control group.
  • CONCLUSION: Our findings may suggest a mechanism for escape of leukemic cells from NK cell immunity.
  • [MeSH-major] Genetic Predisposition to Disease. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / immunology. Receptors, KIR / genetics. Receptors, KIR / immunology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371915.001).
  • [ISSN] 1735-1383
  • [Journal-full-title] Iranian journal of immunology : IJI
  • [ISO-abbreviation] Iran J Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / KIR2DS3 protein, human; 0 / Ligands; 0 / Receptors, KIR
  •  go-up   go-down


75. Xavier AC, Ge Y, Taub JW: Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology. J Mol Diagn; 2009 Sep;11(5):371-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DS children have a approximately 10- to 20-fold higher risk for developing acute lymphoblastic leukemia and acute myeloid leukemia (AML), as compared with non-DS children, although they do not have a uniformly increased risk of developing solid tumors.
  • DS children with acute lymphoblastic leukemia frequently experience higher levels of treatment-related toxicity and inferior event-free survival rates, as compared with non-DS children.
  • DS children also develop AML with unique features and have a 500-fold increased risk of developing the AML subtype, acute megakaryocytic leukemia (AMkL; M7).
  • Nearly 10% of DS newborns are diagnosed with a variant of AMkL, the transient myeloproliferative disorder, which can resolve spontaneously without treatment; event-free survival rates for DS patients with AMkL ranges from 80% to 100%, in comparison with <30% for non-DS children with AMkL.
  • In addition, somatic mutations of the GATA1 gene have been detected in nearly all DS TMD and AMkL cases and not in leukemia cases in non-DS children.
  • Examining leukemogenesis in DS children may identify factors linked to the general development of childhood leukemia and lead to potential new therapeutic strategies to fight this disease.
  • [MeSH-minor] Animals. Disease-Free Survival. GATA1 Transcription Factor / genetics. Humans. Leukemia, Megakaryoblastic, Acute / epidemiology. Leukemia, Megakaryoblastic, Acute / etiology. Leukemia, Megakaryoblastic, Acute / genetics. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / etiology. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2008 Aug;93(8):1262-3 [18519512.001]
  • [Cites] Br J Haematol. 2008 Aug;142(4):610-5 [18510680.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2572-7 [18829445.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1813-7 [18754026.001]
  • [Cites] Lancet. 2008 Oct 25;372(9648):1484-92 [18805579.001]
  • [Cites] Pediatr Blood Cancer. 2009 Jan;52(1):14-9 [18802938.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4507-11 [18689547.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4503-6 [18812473.001]
  • [Cites] Eur J Haematol. 2009 Jan;82(1):46-53 [19067745.001]
  • [Cites] Blood. 2009 Jan 15;113(3):646-8 [18927438.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1575-83 [17971484.001]
  • [Cites] Blood. 2002 Jan 1;99(1):245-51 [11756178.001]
  • [Cites] Leuk Res. 1994 Mar;18(3):163-71 [8139285.001]
  • [Cites] Med Pediatr Oncol. 1995 May;24(5):305-9 [7700182.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3395-403 [8605357.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Med Hypotheses. 1996 Apr;46(4):393-9 [8733171.001]
  • [Cites] Eur J Hum Genet. 2001 Nov;9(11):811-4 [11781696.001]
  • [Cites] Int J Hematol. 2001 Dec;74(4):428-36 [11794699.001]
  • [Cites] Hum Mol Genet. 2002 Jan 15;11(2):147-52 [11809723.001]
  • [Cites] Bull Acad Natl Med. 2001;185(7):1239-52; discussion 1252-4 [11975321.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] Leukemia. 2003 Feb;17(2):277-82 [12592323.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):930-8 [12648061.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):197-9 [12714896.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4301-4 [12586620.001]
  • [Cites] Blood. 2003 Aug 1;102(3):981-6 [12649131.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3415-22 [12885836.001]
  • [Cites] Blood. 2004 Jan 1;103(1):366 [14684662.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):728-35 [14744791.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2480-9 [14656875.001]
  • [Cites] Leuk Lymphoma. 2004 Jan;45(1):19-25 [15061193.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1588-9 [15317736.001]
  • [Cites] Lancet. 1986 Oct 18;2(8512):914 [2876340.001]
  • [Cites] Eur J Pediatr. 1987 Jul;146(4):416-22 [2958283.001]
  • [Cites] Am J Med Genet Suppl. 1990;7:204-12 [2149949.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):993-9 [2069856.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2210-4 [1384797.001]
  • [Cites] Pathol Res Pract. 1996 Dec;192(12):1266-9 [9182298.001]
  • [Cites] Cell. 1997 Jul 11;90(1):109-19 [9230307.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3965-73 [9233806.001]
  • [Cites] Blood. 1998 Jan 15;91(2):608-15 [9427716.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):448-52 [9458088.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1393-400 [10438727.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50537-54 [15448146.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1866-72 [15520821.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):21-8 [15368546.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):33-9 [15390307.001]
  • [Cites] Semin Cell Dev Biol. 2005 Feb;16(1):137-47 [15659348.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):226-31 [15687366.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):797-804 [15755283.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):613-9 [15895080.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):405-10 [15952191.001]
  • [Cites] Pediatr Hematol Oncol. 2005 Apr-May;22(3):229-34 [16020107.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1355-60 [15920490.001]
  • [Cites] Leuk Res. 2005 Nov;29(11):1353-6 [15916804.001]
  • [Cites] Ophthalmic Genet. 2005 Sep;26(3):151-2 [16272063.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4043-9 [16109782.001]
  • [Cites] J Pediatr. 2005 Dec;147(6):748-52 [16356424.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Jan 6;54(51):1301-5 [16397457.001]
  • [Cites] Leukemia. 2006 Feb;20(2):381-3 [16341038.001]
  • [Cites] Br J Haematol. 2006 Mar;132(5):576-83 [16445830.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1570-81 [16249385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3339-44 [16492768.001]
  • [Cites] Br J Haematol. 2006 Jun;133(6):646-8 [16704441.001]
  • [Cites] J Pediatr. 2006 May;148(5):687-9 [16737888.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4606-13 [16469874.001]
  • [Cites] Pediatrics. 2006 Nov;118(5):e1499-508 [17030598.001]
  • [Cites] Pediatr Blood Cancer. 2007 Oct 15;49(5):624-8 [17610268.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2128-31 [17576817.001]
  • [Cites] Cancer. 2007 Nov 1;110(9):2067-74 [17849462.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5442-7 [18048827.001]
  • [Cites] Nature. 2008 Jan 3;451(7174):73-5 [18172498.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):414-20 [18202418.001]
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • [Cites] Leukemia. 2000 May;14(5):943-4 [10803530.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Mar-Apr;23(3):175-8 [11305722.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3727-32 [11389009.001]
  • [Cites] Blood. 2001 Jul 1;98(1):85-92 [11418466.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;67:131-62 [11525381.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2681-8 [11675338.001]
  • [Cites] Blood. 2008 Mar 15;111(6):2991-8 [18182574.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1428-30 [18059480.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):515-21 [18521927.001]
  • (PMID = 19710397.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120772
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human
  • [Number-of-references] 87
  • [Other-IDs] NLM/ PMC2729834
  •  go-up   go-down


76. Hu SY, Chen ZX, Gu WY, Cen JN, Zhao Y, Gu M: [Detection of RbAp46 expression in bone marrow cells of leukemia patients by real-time quantitative RT-PCR]. Zhonghua Xue Ye Xue Za Zhi; 2005 Jul;26(7):417-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of RbAp46 expression in bone marrow cells of leukemia patients by real-time quantitative RT-PCR].
  • OBJECTIVE: To investigate retinoblastoma (Rb) associated protein 46 (RbAp46) gene expression levels in bone marrow (BM) cells of leukemia patients.
  • METHODS: Real-time quantitative reverse polymerase chain reaction (QRT-PCR) method was used for detecting RbAp46 expression levels in BM cells of 140 patients with acute leukemia (AL), 13 with chronic myelogenous leukemia in chronic phase (CML-CP), 7 with CML in blast crisis (CML-BC) and 32 with non-leukemic disorders.
  • RESULTS: The M-Estimators of RbAp46 were higher in 98 newly diagnosed ALs and 5 relapsed ALs than in 28 ALs in complete remission (CR) and 32 non-leukemic controls (178.23 and 213.65 vs 85.89 and 88.08, respectively).
  • CONCLUSION: RbAp46 expression levels in ALs and CML-BC were strikingly higher than that in non-leukemias and CML-CP, and might participate in leukemogenesis.
  • [MeSH-major] Carrier Proteins / genetics. Leukemia / genetics. Nuclear Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16251025.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / RBBP7 protein, human; 0 / Retinoblastoma-Binding Protein 7
  •  go-up   go-down


77. Ramanarayanan J, Mehdi S, Brodzik F, Pasquale D: Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib. Hematology; 2007 Dec;12(6):505-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib.
  • Imatinib, a selective ABL kinase inhibitor has improved therapeutic outcome in patients with Philadelphia positive chronic or acute leukemia.
  • In the present study, we describe a 56-year-old male with Philadelphia chromosome positive acute lymphocytic leukemia (ALL) who was treated with up-front single agent imatinib and achieved complete hematologic, cytogenetic and molecular remission.
  • At relapse 11 months later, new chromosomal translocations involving chromosomes 1, 7 and 4 and cryptic addition to chromosome 11 were identified in Ph+ cells and the patient had rapid deterioration with progressive disease.
  • The significance of additional chromosomal abnormalities in imatinib treated patients and secondary chromosomal abnormalities in Philadelphia positive chronic myeloid leukemia and ALL are discussed briefly in this report.
  • [MeSH-major] Chromosomes, Human, Pair 11. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Pyrimidines / therapeutic use. Thiazoles / therapeutic use. Translocation, Genetic

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852464.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; RBZ1571X5H / Dasatinib
  •  go-up   go-down


78. Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, von Baum H, Marre R: Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis; 2005 Feb;24(2):111-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.
  • The aim of the present study was to investigate the epidemiologic evolution of fluoroquinolone resistance of E. coli clinical isolates from patients admitted to a hematology-oncology service where fluoroquinolone prophylaxis during neutropenia was recommended as the standard of care for many years but was then discontinued in a trial conducted in patients with acute leukemia.
  • Epidemiologic surveillance of fluoroquinolone resistance of E. coli clinical isolates at our cancer center since 1992 showed a continuing influx of new clones not previously observed in the population of cancer patients, an increase in the number of cancer patients per year colonized and/or infected by fluoroquinolone-resistant E. coli (1992-1994, 10-16 patients; 1995-1997, 24-27 patients), and a resistance rate of >50% among E. coli bloodstream isolates of hematology-oncology patients.
  • A 6-month fluoroquinolone prophylaxis discontinuation intervention trial in 1998 suggested that despite increasing resistance among E. coli isolates, fluoroquinolone prophylaxis in acute leukemia patients was still effective in the prevention of gram-negative bacteremia (incidence rates, 8% during the pre-intervention period vs. 20% after discontinuation; p<0.01).
  • The resumption of fluoroquinolone prophylaxis in acute leukemia patients thereafter decreased the incidence of gram-negative bacteremia to the pre-intervention level (9%; p=0.03), while the proportion of in vitro fluoroquinolone resistance in E. coli bacteremia isolates again increased (from 15% during the intervention period to >50% in the post-intervention period).
  • [MeSH-major] Anti-Infective Agents / pharmacology. Drug Resistance, Bacterial. Escherichia coli / drug effects. Escherichia coli Infections / prevention & control. Fluoroquinolones / pharmacology. Leukemia / complications. Neutropenia / complications

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - E. Coli Infections.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Clin Microbiol Infect Dis. 2005 Feb;24(2):109-10 [15714331.001]
  • [Cites] Clin Lab Haematol. 2001 Feb;23 (1):39-42 [11422229.001]
  • [Cites] Clin Infect Dis. 1997 Aug;25(2):346-8 [9332551.001]
  • [Cites] J Hematother Stem Cell Res. 2001 Dec;10(6):895-903 [11798516.001]
  • [Cites] Schweiz Med Wochenschr. 2000 Dec 2;130(48):1837-44 [11132527.001]
  • [Cites] Clin Infect Dis. 2002 Mar 15;34(6):730-51 [11850858.001]
  • [Cites] Am J Med. 1994 Sep;97(3):256-64 [8092175.001]
  • [Cites] Indian J Med Res. 2001 Dec;114:207-11 [12040764.001]
  • [Cites] Leuk Lymphoma. 1999 Aug;34(5-6):585-9 [10492083.001]
  • [Cites] J Antimicrob Chemother. 1992 Nov;30(5):730-1 [1493993.001]
  • [Cites] Clin Infect Dis. 1997 Dec;25(6):1385-91 [9431383.001]
  • [Cites] Clin Infect Dis. 1999 Sep;29(3):490-4 [10530434.001]
  • [Cites] Antimicrob Agents Chemother. 1996 Feb;40(2):503-5 [8834911.001]
  • [Cites] N Engl J Med. 1994 Apr 28;330(17):1240-1 [8139646.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23(1):27-33 [10037047.001]
  • [Cites] J Antimicrob Chemother. 1988 Dec;22(6):953-4 [3149635.001]
  • [Cites] Vet Microbiol. 1998 Nov;64(1):75-81 [9874105.001]
  • [Cites] Clin Microbiol Infect. 1999 Aug;5(8):457-461 [11856289.001]
  • [Cites] Infection. 1991 Mar-Apr;19(2):73-80 [2050424.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1359-68 [11762805.001]
  • [Cites] Med Clin (Barc). 2003 Mar 15;120(9):321-5 [12646106.001]
  • [Cites] Curr Clin Top Infect Dis. 1988;9:1-43 [3077285.001]
  • [Cites] Emerg Infect Dis. 2001 Sep-Oct;7(5):862-71 [11747700.001]
  • [Cites] Clin Infect Dis. 1998 Jul;27(1):235-7 [9675498.001]
  • [Cites] Bone Marrow Transplant. 2004 Apr;33(8):847-53 [14755314.001]
  • [Cites] Clin Infect Dis. 1995 Apr;20(4):907-12 [7795093.001]
  • [Cites] Oncol Rep. 1994 Nov;1(6):1101-5 [21607499.001]
  • [Cites] Clin Infect Dis. 1995 Mar;20(3):557-60; discussion 561-3 [7756475.001]
  • [Cites] J Med Microbiol. 1997 Jun;46(6):506-10 [9350204.001]
  • [Cites] Intern Med. 1993 Sep;32(9):710-5 [8142675.001]
  • [Cites] Infection. 1998 Nov-Dec;26(6):379-84 [9861564.001]
  • [Cites] Acta Haematol. 1998;99(4):206-11 [9644298.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):46-52 [11722408.001]
  • [Cites] Clin Infect Dis. 1996 Oct;23(4):795-805 [8909847.001]
  • [Cites] Antimicrob Agents Chemother. 1994 Apr;38(4):681-7 [8031031.001]
  • [Cites] Eur J Cancer. 1992;28A(4-5):873-8 [1524913.001]
  • [Cites] Lung Cancer. 1998 Feb;19(2):121-5 [9567248.001]
  • [Cites] Ann Intern Med. 1987 Jan;106(1):7-11 [3466563.001]
  • [Cites] Enferm Infecc Microbiol Clin. 2001 Nov;19(9):422-7 [11709119.001]
  • [Cites] Ann Intern Med. 1996 Aug 1;125(3):183-90 [8686975.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):1005-11 [8164024.001]
  • [Cites] Med Clin (Barc). 1994 Jan 29;102(3):81-5 [8133717.001]
  • [Cites] J Antimicrob Chemother. 1999 Jul;44(1):117-20 [10459819.001]
  • [Cites] Antimicrob Agents Chemother. 1994 Mar;38(3):465-72 [8203838.001]
  • [Cites] Transplantation. 1991 Mar;51(3):630-6 [2006519.001]
  • [Cites] Antimicrob Agents Chemother. 1993 Mar;37(3):474-82 [8460916.001]
  • [Cites] Infection. 2000 Sep;28(5):278-81 [11073133.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):419-24 [12518366.001]
  • [Cites] Clin Infect Dis. 2002 Jun 1;34(11):1469-74 [12015693.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2001 Sep;20(9):657-60 [11714050.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1998 Aug;17(8):591-2 [9796662.001]
  • [Cites] Bone Marrow Transplant. 1999 Dec;24(11):1207-11 [10642810.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1179-87 [9508206.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):93-7 [3132393.001]
  • [Cites] Antimicrob Agents Chemother. 1990 Feb;34(2):215-8 [2327768.001]
  • [Cites] Lancet. 1997 Feb 8;349(9049):403 [9033478.001]
  • [Cites] Antimicrob Agents Chemother. 1996 Feb;40(2):387-92 [8834885.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2126-34 [10811678.001]
  • (PMID = 15714332.001).
  • [ISSN] 0934-9723
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Fluoroquinolones
  •  go-up   go-down


79. Dinçol G, Palandüz S, Nalçaci M, Uçur A, Büyükaydin B: Myeloid/natural killer cell precursor acute leukemia with tetraploidy. Cancer Genet Cytogenet; 2005 Dec;163(2):156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid/natural killer cell precursor acute leukemia with tetraploidy.
  • Myeloid/natural killer (NK) cell precursor acute leukemia is characterized by coexpression of myeloid and natural killer cell antigens and an aggressive clinical course.
  • Here we report a case of myeloid/NK precursor acute leukemia in a 37-year-old woman.
  • Clinical presentation was correlated with leukemic blast morphology, immunophenotype, and cytogenetic analysis.
  • Peripheral blood smears and bone marrow aspirate smears at presentation revealed blastic cells, which were generally L2 shaped, with variation in cell size, round to moderately irregular nuclei and prominent nucleoli, pale cytoplasm, and a lack of azurophilic granules.
  • Immunophenotypic analysis of the blasts displayed coexpression of myeloid and natural killer cell antigens with relatively immature phenotype: CD7+, CD33+, CD34+, CD56+, CD57+, CD16-, MPO-.
  • Fluorescence in situ hybridization analysis revealed the same abnormality.
  • The patient did not respond to chemotherapy (cytosine arabinoside and idarubicin) and died of a septic complication on the 34th day after admission.
  • To our knowledge, this is the first description of tetraploidy in myeloid/NK cell precursor acute leukemia.
  • [MeSH-major] Killer Cells, Natural / immunology. Leukemia, Myeloid / genetics. Polyploidy
  • [MeSH-minor] Acute Disease. Adult. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Tetraploidy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16337859.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Nguyen-Khac F, Davi F, Receveur A, Maloum K, Morel V, Le Garff-Tavernier M, Ong J, Berger R, Leblond V, Merle-Béral H: Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin. Cancer Genet Cytogenet; 2005 May;159(1):74-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin.
  • Burkitt-type acute leukemia cells were present in the bone marrow of a patient with B-prolymphocytic leukemia diagnosed from peripheral blood cell morphology.
  • These data indicated the common origin of the two coexisting leukemias and are the first example of such occurrence in a leukemic patient.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 8 / genetics. Leukemia, Prolymphocytic / genetics. Neoplasms, Second Primary / genetics. Translocation, Genetic
  • [MeSH-minor] Bone Marrow / pathology. Cell Lineage. Cytogenetic Analysis. Female. Gene Rearrangement. Genes, myc. Humans. In Situ Hybridization, Fluorescence. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860362.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Li ZY, Liu DP, Liang CC: New insight into the molecular mechanisms of MLL-associated leukemia. Leukemia; 2005 Feb;19(2):183-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New insight into the molecular mechanisms of MLL-associated leukemia.
  • Rearrangements of the MLL gene (ALL1, HRX, and Hrtx) located at chromosome band 11q23 are commonly involved in adult and pediatric cases of primary acute leukemias and also found in cases of therapy-related secondary leukemias.
  • Studies on mouse models of MLL translocation and cell lines containing MLL rearrangements showed that the MLL gene linked chromosomal rearrangements to cellular differentiation and tumor tropism.
  • [MeSH-major] DNA-Binding Proteins / genetics. Leukemia / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics
  • [MeSH-minor] Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. Mutation. Myeloid-Lymphoid Leukemia Protein. Zinc Fingers / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15618964.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 89
  •  go-up   go-down


82. Rahman MM, Khan MA: Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia. Bangladesh Med Res Counc Bull; 2009 Dec;35(3):91-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia.
  • Infection in chemotherapy-induced neutropenia (neutrophils < 500/mm3) is the main cause of death during the treatment of acute leukemia.
  • Eighty patients of acute leukemia was randomly assigned to had levofoxacin (500 mg/daily) or placebo from the starting of chemotherapy.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / adverse effects. Bacterial Infections / prevention & control. Leukemia / blood. Leukemia / microbiology. Levofloxacin. Neutropenia / microbiology. Ofloxacin / therapeutic use
  • [MeSH-minor] Acute Disease. Adult. Antibiotic Prophylaxis. Female. Humans. Male. Single-Blind Method

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. Levofloxacin .
  • Hazardous Substances Data Bank. Ofloxacin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20922911.001).
  • [ISSN] 0377-9238
  • [Journal-full-title] Bangladesh Medical Research Council bulletin
  • [ISO-abbreviation] Bangladesh Med Res Counc Bull
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Bangladesh
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 6GNT3Y5LMF / Levofloxacin; A4P49JAZ9H / Ofloxacin
  •  go-up   go-down


83. Hashii Y, Sato E, Ohta H, Oka Y, Sugiyama H, Ozono K: WT1 peptide immunotherapy for cancer in children and young adults. Pediatr Blood Cancer; 2010 Aug;55(2):352-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the efficacy of WT1 vaccination for five children with solid cancer or acute leukemia.
  • One patient showed complete response and one patient showed stable disease according to the Response Evaluation Criteria in Solid Tumors; the remaining three showed progressive disease.
  • These results suggest that WT1 vaccination has therapeutic potential, but any beneficial effect may be insufficient in the presence of gross residual disease.
  • [MeSH-minor] Adolescent. Child. Erythema / chemically induced. Female. HLA-A Antigens. HLA-A24 Antigen. Humans. Leukemia / therapy. Male. Peptide Fragments / administration & dosage. Peptide Fragments / therapeutic use. T-Lymphocytes, Cytotoxic / immunology. Treatment Outcome. Vaccination. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Immunotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20582983.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-A Antigens; 0 / HLA-A*24:02 antigen; 0 / HLA-A24 Antigen; 0 / Peptide Fragments; 0 / WT1 Proteins
  •  go-up   go-down


84. Xicoy B, Ribera JM, Oriol A, Sanz MA, Abella E, Tormo M, del Potro E, Bueno J, Grande C, Fernández-Calvo J, Orts M, Novo A, Rivas C, Hernández-Rivas JM, Feliu E, Ortega JJ: [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]. Med Clin (Barc); 2006 Jan 21;126(2):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients].
  • [Transliterated title] Significado pronóstico de los subtipos inmunológicos de la leucemia aguda linfoblástica T del adulto. Estudio de 81 pacientes.
  • BACKGROUND AND OBJECTIVE: T-cell acute lymphoblastic leukemia (ALL) includes 4 immunological subtypes: pro-T, pre-T, thymic or cortical and mature.
  • The objective of this study was to describe the clinical characteristics, the result of treatment and the prognosis of the immunological subtypes of T-cell ALL in 81 adult patients included in 2 protocols of the Spanish PETHEMA group (ALL-96 and ALL-93).
  • The main clinical and biological parameters as well as the rate of response to treatment, the frequency of complete remission , disease free survival and overall survival were compared in each T-cell ALL subtype.
  • Patients with mature T-cell ALL had a slow rate of response to treatment in comparison with patients wit pre-T and mature T-cell ALL but this did not translate to significant differences in frequency of complete remission (77% vs 94%), disease free survival (42% vs 46%) and overall survival (29% vs 47%).
  • CONCLUSIONS: Although patients with mature T-cell ALL had a slow rate of response to treatment and their survival tended to be shorter, in the present study there were no statistically significant differences in the prognosis of the different subtypes of T-cell ALL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426542.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


85. Hernández-Morales AL, Zonana-Nacach A, Zaragoza-Sandoval VM: [Associated risk factors in acute leukemia in children. A cases and controls study]. Rev Med Inst Mex Seguro Soc; 2009 Sep-Oct;47(5):497-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Associated risk factors in acute leukemia in children. A cases and controls study].
  • [Transliterated title] Factores asociados a leucemia aguda en niños. Estudio de casos y controles.
  • OBJECTIVE: To investigate the risk factors associated with childhood acute leukemia (CHAL).
  • A non-significant frequency was observed with previous fetal death, neonatal jaundice, smoking 3 months before pregnancy, father intake of alcohol, pesticides use during pregnancy at home or garden and living close (< 60 m) to agricultural fields.
  • [MeSH-major] Leukemia, Myeloid, Acute. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20550859.001).
  • [ISSN] 0443-5117
  • [Journal-full-title] Revista médica del Instituto Mexicano del Seguro Social
  • [ISO-abbreviation] Rev Med Inst Mex Seguro Soc
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


86. Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, Passamonti F, Invernizzi R, Castello A, Magrini U, Lazzarino M, Cazzola M: Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol; 2009 Feb 10;27(5):754-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
  • CD34+ cell clusters were found in 23% of patients and were associated with WHO categories with excess of blasts (P < .001) and poor-risk cytogenetics (P = .001).
  • In multivariable analysis, BM fibrosis and presence of CD34+ cell clusters had independent negative impact on overall survival (P < .001 and P = .019, respectively) and leukemia-free survival (P < .001 and P = .004, respectively).
  • One cluster consisted mainly of patients with BM fibrosis, multilineage dysplasia, and high transfusion requirement; these individuals had lower overall survival and leukemia-free survival (P = .001 and P < .001, respectively).
  • Furthermore, the presence of CD34+ cell clusters is an independent risk factor for progression to acute leukemia.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fibrosis. Humans. Leukemia, Myelomonocytic, Acute / pathology. Male. Middle Aged. Prognosis. Retrospective Studies


87. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C: Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res; 2005 Sep 15;11(18):6641-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
  • PURPOSE: To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and carboplatin in adults with recurrent or refractory acute leukemias.
  • Among 45 evaluable patients, there were 7 complete remissions, 2 partial remissions, 1 incomplete complete remission, and 1 reversion to chronic-phase chronic myelogenous leukemia.
  • Leukemic cell levels of topoisomerase I, checkpoint kinase 1, checkpoint kinase 2, and Mcl-1 correlated with proliferating cell nuclear antigen but not with response.
  • Responses seem to correlate with low pretreatment blast cell Bcl-2 expression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Bone Marrow Cells / drug effects. Bone Marrow Cells / metabolism. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carboplatin / pharmacokinetics. Cell Cycle Proteins / metabolism. Combined Modality Therapy. DNA Topoisomerases, Type I / metabolism. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. HL-60 Cells. Hematopoietic Stem Cell Transplantation. Humans. Immunoblotting. Infusions, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local. Proliferating Cell Nuclear Antigen / metabolism. Topotecan / administration & dosage. Topotecan / adverse effects. Topotecan / pharmacokinetics. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166443.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA73709; United States / NCI NIH HHS / CA / U01 CA69854; United States / NCI NIH HHS / CA / U01 CA69912
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Proliferating Cell Nuclear Antigen; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; EC 5.99.1.2 / DNA Topoisomerases, Type I
  •  go-up   go-down


88. Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A, Volin L, Gürman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC, Kolb HJ, Rocha V, EBMT Acute Leukemia Working Party: Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol; 2007 Nov 1;25(31):4938-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
  • PURPOSE: To evaluate the role of donor lymphocyte infusion (DLI) in the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT).
  • Two-year survival was 56% +/- 10%, if DLI was performed in remission or with favorable karyotype, and 15% +/- 3% if DLI was given in aplasia or with active disease.
  • CONCLUSION: Although further evidence for a graft-versus-leukemia effect by DLI is provided, our results confirm, that the clinical benefit is limited to a minority of patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Lymphocyte Transfusion. Neoplasm Recurrence, Local / therapy


89. Knüttgen D, Kamp M, Ströhlein M, Matten J, Chemaissani A, Ernestus K, Sakka SG, Wappler F: [Invasive pulmonary aspergillosis. Occurrence in a non-neutropenic female patient with abdominal sepsis]. Anaesthesist; 2009 Mar;58(3):262-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Invasive pulmonary aspergillosis. Occurrence in a non-neutropenic female patient with abdominal sepsis].
  • Invasive pulmonary aspergillosis (IPA) is a life-threatening infection predominantly affecting immunocompromised patients, e.g. with acute leukemia.
  • This case report demonstrates that IPA can also occur in non-neutropenic critically ill surgical patients.
  • The case of a 63-year-old woman is reported, who developed IPA of the respiratory tract in the course of diffuse purulent peritonitis.
  • However, application of caspofungin, intensive kinetic therapy (including prone position) and airway management by interventional bronchoscopy enabled successful treatment of this severe complication.

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2006 Oct;130(4):1143-9 [17035449.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2605-17 [14633632.001]
  • [Cites] Arch Intern Med. 1989 Jan;149(1):30-5 [2643417.001]
  • [Cites] Intensive Care Med. 2007 Oct;33(10):1694-703 [17646966.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Jun;34(2):293-313, viii [15850843.001]
  • [Cites] Clin Infect Dis. 2004 Dec 1;39(11):1563-71 [15578352.001]
  • [Cites] Microbiology. 1994 Sep;140 ( Pt 9):2475-9 [7952197.001]
  • [Cites] J Chemother. 2007 Jun;19(3):339-42 [17594932.001]
  • [Cites] Br J Radiol. 2001 Oct;74(886):955-8 [11675315.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):408-15 [12167683.001]
  • [Cites] Cancer. 2006 Dec 15;107(12 ):2888-97 [17103444.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Sep 15;170(6):621-5 [15229094.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1989 Sep;98(9):718-20 [2675730.001]
  • (PMID = 19247622.001).
  • [ISSN] 1432-055X
  • [Journal-full-title] Der Anaesthesist
  • [ISO-abbreviation] Anaesthesist
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Lipopeptides; 0 / Pyrimidines; 0 / Triazoles; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole
  •  go-up   go-down


90. Kume T, Akasaka T, Kawamoto T, Watanabe N, Toyota E, Sukmawan R, Sadahira Y, Yoshida K: Visualization of neointima formation by optical coherence tomography. Int Heart J; 2005 Nov;46(6):1133-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our male patient, who had been treated with a coronary stent, died due to acute leukemia.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16394609.001).
  • [ISSN] 1349-2365
  • [Journal-full-title] International heart journal
  • [ISO-abbreviation] Int Heart J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


91. Wang SA: Diagnosis of Myelodysplastic Syndromes in Cytopenic Patients. Surg Pathol Clin; 2010 Dec;3(4):1127-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of Myelodysplastic Syndromes in Cytopenic Patients.
  • For pathologists and hematopathologists who examine the bone marrow (BM), a diagnosis of cytopenia secondary to an infiltrative BM process or acute leukemia can be readily established based on morphologic evaluation and flow cytometry immunophenotyping.
  • However, it can be more challenging to establish a diagnosis of myelodysplastic syndrome (MDS).
  • In this article, the practical approaches for establishing or excluding a diagnosis of MDS (especially low-grade MDS) in patients with clinical cytopenia are discussed along with the current diagnostic recommendations provided by the World Health Organization and the International Working Group for MDS.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 26839301.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Algorithm / Aplastic anemia / Cytogenetics / Cytopenia / Diagnostic criteria / Flow cytometry / Myelodysplastic syndromes
  •  go-up   go-down


92. Liu H, Wang M, Diao S, Rao Q, Zhang X, Xing H, Wang J: siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53. Leuk Res; 2009 Sep;33(9):1243-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53.
  • Our previous study revealed that the expression of iASPP in acute leukemia (AL) patients was higher than that of normal control which implied that iASPP might play an important role in the pathogenesis and/or disease progression of AL.
  • In this study, the iASPP expression was blocked by RNA interference (RNAi) in two leukemic cell lines, Nalm6 and K562, to explore the effects of iASPP on leukemia cells.
  • The results indicated that down-regulation of endogenous iASPP increased p53-dependent apoptosis of leukemia cells.
  • Thus, iASPP could be a molecular target in leukemia therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / genetics. Daunorubicin / pharmacology. Down-Regulation. Etoposide / pharmacology. Intracellular Signaling Peptides and Proteins / genetics. Leukemia / pathology. RNA, Small Interfering / genetics. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Base Sequence. Cell Division / genetics. Cell Line, Tumor. DNA Primers. Humans. RNA, Messenger / genetics. Repressor Proteins

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2009 Sep;33(9):1175-7 [19481801.001]
  • (PMID = 19299014.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Primers; 0 / Intracellular Signaling Peptides and Proteins; 0 / PPP1R13L protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Repressor Proteins; 0 / Tumor Suppressor Protein p53; 6PLQ3CP4P3 / Etoposide; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


93. Bozkurt SU, Berrak SG, Tugtepe H, Canpolat C, Palanduz S, Tecimer T: Acute megakaryoblastic leukemia mimicking small round cell tumor with novel t(1;5)(q21;p13). APMIS; 2008 Feb;116(2):163-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute megakaryoblastic leukemia mimicking small round cell tumor with novel t(1;5)(q21;p13).
  • Acute megakaryoblastic leukemia is a relatively rare form of acute leukemia that has heterogeneous blast morphology and karyotypic abnormalities.
  • An 8-month-old boy with a retroperitoneal mass was diagnosed as having acute megakaryoblastic leukemia that initially presented as small round cell tumor of childhood.
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 5. Leukemia, Megakaryoblastic, Acute / genetics. Retroperitoneal Neoplasms / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18321370.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 9001-27-8 / Factor VIII
  •  go-up   go-down


94. Wang Y, Armstrong SA: Genome-wide SNP analysis in cancer: leukemia shows the way. Cancer Cell; 2007 Apr;11(4):308-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide SNP analysis in cancer: leukemia shows the way.
  • The application of novel genetic/genomic technologies to the study of acute leukemia has frequently been a proving ground for such approaches in cancer.
  • A recent study by Mullighan et al. uses SNP arrays to assess copy number alterations in a large group of childhood acute lymphoblastic leukemias and demonstrates frequent mutation of genes encoding transcription factors important for B cell development.
  • These studies not only provide information about the multistep development of leukemia, but also demonstrate the potential for this approach in other cancers.
  • [MeSH-major] Genome, Human. Leukemia / genetics. Polymorphism, Single Nucleotide / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418407.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


95. Ren CM, Luo WD, Feng CW: [One case of benzene induced acute leukemia]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2009 Jan;27(1):20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [One case of benzene induced acute leukemia].
  • [MeSH-major] Benzene / poisoning. Leukemia / chemically induced. Occupational Exposure / adverse effects
  • [MeSH-minor] Acute Disease. Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. BENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224687.001).
  • [ISSN] 1001-9391
  • [Journal-full-title] Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
  • [ISO-abbreviation] Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] J64922108F / Benzene
  •  go-up   go-down


96. Kim MK, Mun YC, Seong CM, Chung WS, Huh J: [Variant Philadelphia chromosome identified by interphase fluorescence in situ hybridization (FISH) without evidence on G-banded karyotyping and metaphase FISH]. Korean J Lab Med; 2010 Dec;30(6):711-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 52-year-old man was diagnosed with acute leukemia of mixed phenotype.
  • The other case was that of a 31-yr-old male patient diagnosed with CML in the blastic phase.
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 9. Humans. Interphase. Karyotyping. Leukemia / diagnosis. Leukemia / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Male. Metaphase. Middle Aged. Phenotype. Translocation, Genetic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157160.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


97. Bishop MM, Lee SJ, Beaumont JL, Andrykowski MA, Rizzo JD, Sobocinski KA, Wingard JR: The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls. Biol Blood Marrow Transplant; 2010 Feb;16(2):207-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls.
  • Little is known about the health promotion, prevention, and disease screening behaviors of cancer survivors treated with hematopoietic cell transplantation (HCT), who undergo arduous treatment and may be at particular risk for late effects and secondary malignancies.
  • Some differences between disease group and type of transplant were found, with survivors of acute leukemia less likely to report regular exercise, autologous transplant survivors more likely than allogeneic transplant survivors to report screenings for breast and cervical cancer, and allogeneic transplant survivors more likely than autologous transplant survivors to report undergoing a skin exam in the previous year.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Healthy Aging.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):599-608 [15659507.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5814-30 [16043830.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8884-93 [16314649.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(3):249-61 [16435004.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Feb;12(2):138-51 [16443512.001]
  • [Cites] J Clin Oncol. 2006 Nov 10;24(32):5125-31 [17093274.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):834-9 [17416780.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2100-6 [17513816.001]
  • [Cites] Semin Oncol Nurs. 2007 Nov;23(4):242-52 [18022052.001]
  • [Cites] Blood. 2008 Jan 15;111(2):939-44 [17911386.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1073-9 [18309941.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Feb;6(2):215-22 [18319053.001]
  • [Cites] Oncol Nurs Forum. 2008 Mar;35(2):E12-22 [18321824.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2198-204 [18445845.001]
  • [Cites] Cancer. 2008 Jun;112(11):2475-82 [18428195.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3242-7 [18591559.001]
  • [Cites] J Cancer Surviv. 2007 Mar;1(1):17-26 [18648941.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):674-84 [10649263.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1712-9 [15386307.001]
  • [Cites] Am J Prev Med. 2005 May;28(4):351-6 [15831340.001]
  • (PMID = 19781657.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA081320-01; United States / NCI NIH HHS / CA / K23 CA082350-02; United States / NCI NIH HHS / CA / K23 CA082350; United States / NCI NIH HHS / CA / CA082350-01; United States / NCI NIH HHS / CA / CA081320-02; United States / NCI NIH HHS / CA / R01 CA081320-01; United States / NCI NIH HHS / CA / K23 CA082350-01; United States / NCI NIH HHS / CA / CA082350-05; United States / NCI NIH HHS / CA / K23 CA082350-04; United States / NCI NIH HHS / CA / CA082350-02; United States / NCI NIH HHS / CA / CA081320-03; United States / NCI NIH HHS / CA / K23 CA082350-05; United States / NCI NIH HHS / CA / R01 CA81320; United States / NCI NIH HHS / CA / K23 CA082350-03; United States / NCI NIH HHS / CA / CA082350-03; United States / NCI NIH HHS / CA / R01 CA081320-02; United States / NCI NIH HHS / CA / K23 CA82350; United States / NCI NIH HHS / CA / R01 CA081320; United States / NCI NIH HHS / CA / CA082350-04; United States / NCI NIH HHS / CA / R01 CA081320-03
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS148058; NLM/ PMC2819641
  •  go-up   go-down


98. Williams MV, Drinkwater KJ, Jones A, O'Sullivan B, Tait D: Waiting times for systemic cancer therapy in the United Kingdom in 2006. Br J Cancer; 2008 Sep 2;99(5):695-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, urgent treatment should be clearly defined as that required within 24 h (maximum 48 h) to avoid the risk of clinical deterioration, particularly in patients with acute leukaemia, lymphoma or germ cell tumour.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):492-6 [12888818.001]
  • [Cites] Breast Cancer Res Treat. 2006 Oct;99(3):313-21 [16583264.001]
  • [Cites] CMAJ. 2007 Jan 30;176(3):327-32 [17261829.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Jun;19(5):273-86 [17517327.001]
  • [Cites] Radiother Oncol. 2008 Apr;87(1):3-16 [18160158.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):752-3 [17714992.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):784-96 [17714993.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):747 [17714994.001]
  • [Cites] J Thorac Oncol. 2007 Jul;2(7):590-2 [17607113.001]
  • (PMID = 18728658.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2528160
  •  go-up   go-down


99. Bashey A, Donohue M, Liu L, Medina B, Corringham S, Ihasz A, Carrier E, Castro JE, Holman PR, Xu R, Law P, Ball ED, Lane TA: Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Transfusion; 2007 Nov;47(11):2153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
  • BACKGROUND: Interpatient variability in the kinetics of peripheral blood progenitor cell (PBPC) mobilization is commonly seen with conventional chemotherapy-based mobilization regimens.
  • STUDY DESIGN AND METHODS: The efficacy of an approach where LP was invariably commenced on Day 11 after intermediate-dose cyclophosphamide followed by sequential administration of granulocyte-macrophage-colony-stimulating factor (CSF) and granulocyte-CSF (Cy/GM/G) was retrospectively analyzed in 225 consecutive, unselected patients undergoing autologous hematopoietic stem cell transplantation for all diagnoses other than acute leukemia at our center.
  • RESULTS: After Cy/GM/G, a CD34+ cell yield of at least 2.0x10(6) per kg was achieved in 90.7 percent of patients.
  • Optimal yield (OY; >or=5x10(6) or 10x10(6) CD34+ cells/kg depending on diagnosis) was achieved in 67.6 percent of patients.
  • PLT-D1LP and diagnosis of myeloma were associated with a shorter time to achieve a CD34+ cell yield of at least 5x10(6) per kg (p<0.001 and p=0.002, respectively).
  • CONCLUSION: Cy/GM/G with scheduled LP commencement on Day 11 enables optimal CD34+ cell yields in most patients undergoing autologous transplantation, despite a low risk of FN and avoidance of weekend LP.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization / methods. Leukapheresis
  • [MeSH-minor] Adult. Aged. Antigens, CD34. Female. Humans. Kinetics. Male. Middle Aged. Neutropenia. Peripheral Blood Stem Cell Transplantation / methods. Time Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17958545.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


100. Xu B, Li L, Tang JH, Zhou SY: Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia. Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct;25(10):1207-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia.
  • OBJECTIVE: To analyze Fms-like tyrosine kinase 3 (FLT3) gene and FLT3 internal tandem duplication (ITD) mutation in acute lymphoblastic leukemia (ALL) patients of different immunological subtypes.
  • Two cases (3.2%) were found to have FLT3/ITD mutation, which were also positive for myeloid antigen expression and diagnosed as acute mixed-lineage leukemia, showing leukocytosis and high percentage of bone marrow blast cells with poor prognosis.
  • In B-lineage ALL patients, FLT3 gene is more frequent in cases with undifferentiated than those with differentiated blast cells.
  • FLT3/ITD is rarely detected in ALL patients and FLT3/ITD mutation detection might be helpful to identify the genotypes and evaluate the prognosis of acute leukemia.
  • [MeSH-major] Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor Protein-Tyrosine Kinases / genetics. Tandem Repeat Sequences / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234090.001).
  • [ISSN] 1000-2588
  • [Journal-full-title] Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
  • [ISO-abbreviation] Di Yi Jun Yi Da Xue Xue Bao
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down






Advertisement